Symjepi Approved for Emergency Anaphylaxis Treatment
The Food and Drug Administration (FDA) has approved Symjepi (epinephrine injection; Adamis Pharmaceuticals) for the emergency treatment of allergic reactions (Type 1) including anaphylaxis.
Symjepi delivers 0.3mg epinephrine injection and is intended for patients who weigh 30kg or more. It can be injected intramuscularly or subcutaneously, and through clothing if necessary. Symjepi should only be injected into the anterolateral aspect of the thigh; injection into other areas such as the buttocks or the hands and feet may result in adverse effects and may also not provide effective treatment of anaphylaxis.
Symjepi is supplied as a single-dose, pre-filled syringe for manual injection, containing 0.3mg/0.3mL epinephrine sterile solution for injection. Each syringe is overfilled for stability purposes; more than half of the solution remains in the syringe after use and cannot be reused. Each pack contains 1 or 2 pre-filled syringes.
Epinephrine acts on both alpha and beta-adrenergic receptors. Through its action on alpha-adrenergic receptors, epinephrine lessens the vasodilation and increased vascular permeability that occurs during anaphylaxis, which can lead to loss of intravascular fluid volume and hypotension. Through its action on beta-adrenergic receptors, epinephrine causes bronchial smooth muscle relaxation and helps alleviate bronchospasm, wheezing and dyspnea that may occur during anaphylaxis. When given subcutaneously or intramuscularly, epinephrine has a rapid onset and short duration of action.
For more information call (858) 997-2400 or visit AdamisPharma.com.